Chartwell Molecules Patent-Cliff Exposure & CMS Drug Spending Portfolio

Chartwell Molecules (US): 2 reconciled FDA prescription therapies, $7.6M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$7.6M
2024 Medicare Part D Spend$4.2M
2024 Medicaid Spend$3.4M
California HCAI SB 17 Filings1 WAC filings (max 93.7% 2-yr change)